March 10 (Reuters) - Neogenomics Inc NEO.O:
NEOGENOMICS EXPANDS ONCOLOGY TESTING REACH IN THE NORTHEAST WITH ACQUISITION OF PATHLINE
NEOGENOMICS INC: SYNERGIES FROM TRANSACTION EXPECTED TO YIELD ANNUAL COST REDUCTIONS, WHICH WILL BE ACCRETIVE TO AEBITDA STARTING IN 2026